Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy
- PMID: 28643144
- PMCID: PMC7703858
- DOI: 10.1007/s10120-017-0743-4
Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy
Abstract
Background: The American Joint Committee on Cancer (AJCC) recently released its 8th edition staging system, which created a separate staging system for gastric cancer patients who have undergone preoperative therapy (ypStage). The objective of this retrospective study was to apply the new ypStage to patients who have undergone preoperative therapy and potentially curative gastrectomy.
Methods: We collected data from a prospectively maintained institutional database of gastric cancer patients who underwent potentially curative gastrectomy after preoperative therapy (1995-2015). Kaplan-Meier survival estimations and log-rank tests were performed to compare survival. Univariable and multivariable analyses were performed to determine risk factors for overall survival.
Results: A total of 354 patients met our criteria. Most patients completed planned preoperative therapy (94%; 332/354) and received chemoradiation therapy (75%; 265/354). Although clinical stage (cStage) provided a poor discrimination of survival, postneoadjuvant pathological stage (ypStage) identified significant variation in survival (p < 0.001). Multivariable analysis showed the following factors were associated with survival after adjustment for ypStage: Asian race (HR 0.52; p = 0.028), linitis plastica (HR 1.66; p = 0.037), and R1 resection (HR 1.91; p = 0.016). Survival was not longer in ypT0N0 patients than in ypStage I patients (HR 1.29; p = 0.377).
Conclusions: The AJCC 8th edition staging system for gastric cancer demonstrated reasonable survival prediction by ypStage, but not cStage, in patients who had undergone preoperative therapy. ypT0N0 patients, although not defined in the 8th edition, may be considered for inclusion in the ypStage I group.
Keywords: AJCC 8th edition staging system; Gastric cancer; Preoperative therapy; Surgery; Survival.
Conflict of interest statement
Figures
Similar articles
-
The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging.Gastric Cancer. 2018 Jan;21(1):1-9. doi: 10.1007/s10120-017-0765-y. Epub 2017 Sep 25. Gastric Cancer. 2018. PMID: 28948368
-
Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis.Gastric Cancer. 2018 May;21(3):391-400. doi: 10.1007/s10120-017-0770-1. Epub 2017 Oct 20. Gastric Cancer. 2018. PMID: 29052053
-
ypT0 gastric carcinoma after preoperative chemotherapy: a unique status according to AJCC 8th edition cancer staging system.Transl Cancer Res. 2020 Dec;9(12):7384-7393. doi: 10.21037/tcr-20-2426. Transl Cancer Res. 2020. PMID: 35117339 Free PMC article.
-
Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.Dis Esophagus. 2016 Nov;29(8):906-912. doi: 10.1111/dote.12538. Dis Esophagus. 2016. PMID: 27905170 Free PMC article.
-
Revised points and disputed matters in the eighth edition of the TNM staging system for gastric cancer.Jpn J Clin Oncol. 2021 Jul 1;51(7):1024-1027. doi: 10.1093/jjco/hyab069. Jpn J Clin Oncol. 2021. PMID: 33987661 Review.
Cited by
-
Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer.Front Immunol. 2025 Jul 18;16:1624943. doi: 10.3389/fimmu.2025.1624943. eCollection 2025. Front Immunol. 2025. PMID: 40755752 Free PMC article.
-
Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma.Cancers (Basel). 2023 Oct 25;15(21):5137. doi: 10.3390/cancers15215137. Cancers (Basel). 2023. PMID: 37958312 Free PMC article.
-
Is Pathologic Complete Response a Good Predictor for the Long-Term, Clinical Outcome in Patients with Gastric Cancer After Neoadjuvant Chemotherapy? A Retrospective, Multi-institution Study in China.Ann Surg Oncol. 2023 Sep;30(9):5534-5542. doi: 10.1245/s10434-023-13728-5. Epub 2023 Jun 19. Ann Surg Oncol. 2023. PMID: 37332025
-
Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients.Cancers (Basel). 2024 Feb 12;16(4):757. doi: 10.3390/cancers16040757. Cancers (Basel). 2024. PMID: 38398148 Free PMC article.
-
Unplanned reoperation after radical gastrectomy for gastric cancer: causes, risk factors, and long-term prognostic influence.Ther Clin Risk Manag. 2018 May 28;14:965-972. doi: 10.2147/TCRM.S164929. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 29881278 Free PMC article.
References
-
- Amin MB, Edge SB, Greene FL, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
-
- Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J Am Coll Surg. 2015;220(1):48–56. doi:10.1016/j.jamcollsurg.2014.06.023. - DOI - PubMed
-
- Badgwell B Multimodality therapy of localized gastric adenocarcinoma. J Natl Compr Cancer Netw. 2016;14(10):1321–7. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous